IO BIOTECH INC (IOBT)

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head...

Let's take a look at the stocks that are in motion in today's session.

Let's take a look at the stocks that are in motion in today's session.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Which stocks are experiencing notable movement on Tuesday?

These stocks are gapping in today's session

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Stay updated with the stocks that are on the move in today's pre-market session.

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

These stocks are moving in today's after hours session

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Get insights into the top gainers and losers of Friday's after-hours session.

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial...

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences...

IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips IO Biotech (NASDAQ:IOBT) just reported results for the second quarter of 2024.I...

IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024

IOBT stock results show that IO Biotech beat analyst estimates for earnings per share the second quarter of 2024.

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights...

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.

IO Biotech to Present at Jefferies Global Healthcare Conference

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024

IOBT stock results show that IO Biotech beat analyst estimates for earnings per share the first quarter of 2024.

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead...

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103...

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer...

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting ...

IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023

IOBT stock results show that IO Biotech missed analyst estimates for earnings per share the fourth quarter of 2023.

IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips IO Biotech (NASDAQ:IOBT) just reported results for the fourth quarter of 2023.I...

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results...

IO Biotech to Present at 44th Annual Cowen Health Care Conference

IO Biotech to Present at 44th Annual Cowen Health Care Conference ...

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial ...

IO Biotech executive discloses purchase of 10K shares (NASDAQ:IOBT)

Learn about the recent insider trading activity at IO Biotech, including a Chief Accounting Officer's purchase of 10,000 shares.

IO Biotech Announces 2023 Third Quarter Results

IO Biotech Announces 2023 Third Quarter Results...

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences...

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting...

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...